PCI BIOTECH HOLDING ASA financials
PCI BIOTECH HOLDING ASA
5967007LIEEXZXFIGG77 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Other income | NOK 6.7M | NOK 3.0M |
| Operating expenses | NOK 24.7M | NOK 25.2M |
| Operating profit (EBIT) | -NOK 18.0M | -NOK 22.2M |
| Net finance income / (cost) | NOK 1.5M | NOK 1.9M |
| Finance costs | NOK 95.0K | NOK 160.0K |
| Profit before tax | -NOK 16.4M | -NOK 20.3M |
| Income tax expense | NOK 0 | NOK 0 |
| Profit for the year | -NOK 16.4M | -NOK 20.3M |
| Total comprehensive income | -NOK 16.4M | -NOK 20.3M |
| Cash flow statement | ||
| Net cash from operating activities | -NOK 13.8M | -NOK 15.0M |
| Net cash from investing activities | NOK 0 | NOK 0 |
| Net cash from financing activities | -NOK 357.0K | -NOK 442.0K |
| Lease liability payments | NOK 357.0K | NOK 442.0K |
| Net change in cash | -NOK 14.1M | -NOK 15.4M |
| Balance sheet | ||
| Total assets | NOK 31.2M | NOK 44.0M |
| Non-current assets | NOK 310.0K | NOK 297.0K |
| Right-of-use assets | NOK 310.0K | NOK 297.0K |
| Current assets | NOK 30.9M | NOK 43.8M |
| Trade & other receivables | NOK 3.8M | NOK 2.6M |
| Cash & equivalents | NOK 27.1M | NOK 41.2M |
| Total equity | NOK 23.5M | NOK 39.0M |
| Non-current liabilities | NOK 0 | NOK 34.0K |
| Current liabilities | NOK 7.8M | NOK 5.0M |
| Lease liabilities (current) | NOK 336.0K | NOK 319.0K |
| Derived metrics | ||
| Return on equity | -70.0% | -52.0% |
| Cash conversion ratio | 0.84× | 0.74× |
| Other reported items | ||
| Additional Paidin Capital | NOK 22.3M | NOK 37.9M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -NOK 1.3M | NOK 3.6M |
| Adjustments For Depreciation and Amortisation Expense | NOK 303.0K | NOK 371.0K |
| Adjustments For Increase Decrease In Trade Account Payable | NOK 1.0M | NOK 217.0K |
| Adjustments For Sharebased Payments | NOK 827.0K | NOK 2.0M |
| Comprehensive Income Attributable To Owners of Parent | -NOK 16.4M | -NOK 20.3M |
| Current Payables On Social Security and Taxes Other Than Income Tax | NOK 748.0K | NOK 872.0K |
| Equity and Liabilities | NOK 31.2M | NOK 44.0M |
| Finance Income | NOK 1.6M | NOK 2.1M |
| General and Administrative Expense | NOK 8.6M | NOK 9.6M |
| Increase Decrease Through Sharebased Payment Transactions | NOK 827.0K | NOK 2.0M |
| Interest Paid Classified As Operating Activities | NOK 0 | -NOK 1.0K |
| Interest Received Classified As Operating Activities | NOK 1.6M | NOK 2.0M |
| Issue of Equity | — | NOK 0 |
| Issued Capital | NOK 1.1M | NOK 1.1M |
| Liabilities | NOK 7.8M | NOK 5.0M |
| Other Adjustments To Reconcile Profit Loss | NOK 1.7M | -NOK 838.0K |
| Other Comprehensive Income | NOK 0 | NOK 0 |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | NOK 0 | NOK 0 |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | NOK 0 | NOK 0 |
| Other Current Liabilities | NOK 5.0M | NOK 3.1M |
| Other Current Receivables | NOK 3.8M | NOK 2.6M |
| Other Noncurrent Liabilities | NOK 0 | NOK 34.0K |
| Research and Development Expense | NOK 16.1M | NOK 15.6M |
| Retained Earnings | NOK 0 | NOK 0 |
| Trade and Other Current Payables To Trade Suppliers | NOK 1.7M | NOK 712.0K |
Every line item above is a fact tagged in PCI BIOTECH HOLDING ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.